Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$40.80 USD

40.80
2,936,408

+0.43 (1.07%)

Updated Nov 6, 2025 04:00 PM ET

After-Market: $40.54 -0.26 (-0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.63%
2Buy17.80%
3Hold9.42%
4Sell5.10%
5Strong Sell2.04%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (99 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?

by Zacks Equity Research

Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.

    Zacks Equity Research

    Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?

    by Zacks Equity Research

    Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.

      Zacks Equity Research

      Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

      by Zacks Equity Research

      Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

        Zacks Equity Research

        Can Penumbra (PEN) Spring a Surprise this Earnings Season?

        by Zacks Equity Research

        Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.

          Zacks Equity Research

          Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?

          by Zacks Equity Research

          Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.

            Zacks Equity Research

            Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

            by Zacks Equity Research

            Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

              Zacks Equity Research

              Patterson Companies (PDCO) Q3 Earnings: What's in Store?

              by Zacks Equity Research

              Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.

                Arpita Dutt headshot

                Forget Alexion, Buy these 4 Biotech Stocks Instead

                by Arpita Dutt

                We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

                  Zacks Equity Research

                  Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?

                  by Zacks Equity Research

                  Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.

                    Zacks Equity Research

                    Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

                    by Zacks Equity Research

                    Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

                      Zacks Equity Research

                      Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?

                      by Zacks Equity Research

                      Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.

                        Zacks Equity Research

                        BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

                        by Zacks Equity Research

                        We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23

                          Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                          by Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                            Arpita Dutt headshot

                            Forget Gilead, Buy These 5 Biotech Stocks Instead

                            by Arpita Dutt

                            With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

                              Zacks Equity Research

                              ITT Inc. (ITT) Q4 Earnings: What's in Store for the Stock?

                              by Zacks Equity Research

                              ITT Inc. (ITT) is slated to report fourth-quarter 2016 results before the opening bell on Feb 14.

                                Zacks Equity Research

                                Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?

                                by Zacks Equity Research

                                Allscripts Healthcare Solutions Inc. (MDRX) is scheduled to release fourth-quarter 2016 results on Feb 16.

                                  Zacks Equity Research

                                  Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors

                                  by Zacks Equity Research

                                  Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors

                                    Zacks Equity Research

                                    Exelixis (EXEL) Shares March Higher, Can It Continue?

                                    by Zacks Equity Research

                                    As of late, it has definitely been a great time to be an investor in Exelixis, Inc. (EXEL).

                                      Zacks Equity Research

                                      Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?

                                      by Zacks Equity Research

                                      Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.

                                        Zacks Equity Research

                                        Ecolab (ECL): What's in the Cards this Earnings Season?

                                        by Zacks Equity Research

                                        St. Paul, MN-based Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report fourth-quarter 2016 results on Feb 21.

                                          Tirthankar Chakraborty headshot

                                          Buy 4 Stocks Riding High on Superb Earnings Acceleration

                                          by Tirthankar Chakraborty

                                          If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be referred to as earnings acceleration.

                                            Arpita Dutt headshot

                                            5 Drug Stocks Poised to Beat Earnings Estimates in Q4

                                            by Arpita Dutt

                                            Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.

                                              Zacks Equity Research

                                              DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?

                                              by Zacks Equity Research

                                              York, PA-based DENTSPLY Sirona Inc. (XRAY), a dental solutions company, is expected to report fourth-quarter 2016 results on Feb 10.

                                                Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                                by Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                                  Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma

                                                  by Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma